People with diabetes are more prone to have heart attack or stroke. There are an estimated 5.2 people in America that are oblivious that they have it. 18.2 million Americans are recorded to have it and over 13 million are on a prediabetic stage. Studies show that there is an undeniable link between diabetes, heart disease and stroke. In fact 6 out of 10 diabetic patients die from heart disease or also known as cardiovascular disease (CV).
Few months ago, Novo Nordisk broadcast constructive top-line results for Liraglutide also known as Victoza. Now, the company, Novo Nordisk announced that semaglutide, a glucagon-like peptide-1 (GLP-1) analogue that motivate insulin and curbs glucagon emission in a glucose-dependent method, while suppressing appetite and food intake. The trial shows, it can significantly diminish the risk of cardiovascular (CV) death, both non-fatal myocardial infarction known as heart attack and stroke by 26%. According to the study, Semaglutide was given once per week to 3,297 adults with type 2 Diabetes known to have higher (CV) risk. The test came in with considerable positive results based on accretion of initial MACE or Major Adverse Cardiovascular Events, tested in 254 people for 104 weeks of treatment.
Almost 50% of the deaths in diabetic patients are caused by heart disease, therefore reducing the risk of underlying complications such as heart attack and stroke is vital.
Dr. Steven Marso, SUSTAIN 6 examiner and lead author of New England Journal of Medicine publication says that he observed a “reduction in cardiovascular events” during the trial, given at “short trial duration”.
What is SUSTAIN 6? SUSTAIN 6 (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) – is a clinical study conducted by Steven P. Marso, MD, of the Research Medical Center, Kansas City, Missouri, and fellow investigators. It is a Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes. They compared the response and the results of patients that took Semaglutide versus placebo in which both received standard clinical care. The trial started in February 2013 with subjects from 20 different countries that were treated for the whole duration of the test.
However, some adverse effects were noted like gastrointestinal dealings but the incidence of pancreatitis was notable lower with semaglutide vs placebo. In microvascular complications, drastically lesser subjects were treated with (62 [3.8%]) of semaglutide vs. placebo of (100 [6.1%]) and develop or worsen nephropathy. On the other hand, people with semaglutide (50 [3.0%]) vs. placebo (29 [1.8%]) suffered complications like diabetic retinopathy.
Moreover, 39% decreased was noted in non-fatal stroke and a non-significant 26% cut in non-fatal myocardial infarction and a neutral ending of (2% decrease) in CV death after only two years of treatment.
Semaglutide is GLP-1 receptor agonist, proposed to offer the quantifiable benefits of a GLP-1 analogue with lesser injections to people with type 2 diabetes. The trial result was presented in the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016 in Munich, Germany and was also published in New England Journal of Medicine.
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk said that The SUSTAIN 6 results will “strengthen the clinical evidence for the Novo Nordisk GLP-1 receptor agonist portfolio” and that the company will expect regulatory submission this year. The will further search for added benefits afar from glycaemic control and weight loss in adults suffering type 2 diabetes with high cardiovascular risk.
Currently, The Danish Company is formulating the first GLP-1 to be given as a pill rather than an injection, -an oral version of semaglutide, which would be announced soon.